Biotherapy Services Limited

Biotherapy Services Limited is a small, active company based in London, UK, founded eleven years ago in 2013. With £165,251 in assets and a virtual address, it’s a relatively lean operation employing just nine people and overseen by four directors – though no owners are officially listed. The company is an irregular importer, primarily dealing in optical and medical tools and devices, with just one month of import activity recorded as of October 2022.

The company’s website reveals a focus on tissue regeneration and wound healing. It’s developing the RAPID Biodynamic Haematogel, a point-of-care wound care treatment, and conducting clinical trials (RAPID1DFU) to investigate its efficacy in treating diabetic foot ulcers. The company's website also states it operates in biotechnology and human health activities. It has a showroom in London and a dedicated team of clinicians, scientists, and healthcare professionals.

Financially, Biotherapy Services Limited shows a mixed picture. Current assets have decreased by 43% to £170,000, while net assets have fallen 13% to -£1.2 million. Cash reserves have also dropped significantly by 49% to £130,000. However, creditors have decreased by 35%, suggesting improved debt management. The company meets two of the three conditions to be considered small (turnover under £10.2m, assets under £5.1m, and fewer than 50 employees). With no auditor mentioned, the financial statements are unaudited.

The company’s significant losses and reliance on external funding suggest it’s burning through money like a startup, although the clinical trial and proprietary technology offer potential for future growth. The lack of officially listed owners could be a sign of a complex ownership structure or a desire for privacy.

Registered in England/Wales under the registration number 08566712, with a registered address at WC2A 1DT, England, London, 4th Floor, 95 Chancery Lane.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.